Search Results

You are looking at 1 - 5 of 5 items for :

  • Corticotrophic adenoma x
  • Refine by Access: All content x
Clear All
Open access

Dinesh Giri, Federico Roncaroli, Ajay Sinha, Mohammed Didi, and Senthil Senniappan

– 223 . ( doi:10.1023/A:1025321731790 ) 10 Jahangiri A Wagner JR Pekmezci M Hiniker A Chang EF Kunwar S Blevins L Aghi MK 2013 A comprehensive longterm retrospective analysis of silent corticotrophic adenomas vs

Open access

Sharmin Jahan, M A Hasanat, Tahseen Mahmood, Shahed Morshed, Raziul Haq, and Md Fariduddin

M Hiniker A Chang EF Kunwar S Blevins L Aghi MK . A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs. hormone-negative adenomas . Neurosurgery 2013 8 – 17 ; discussion 17. ( https://doi.org/10

Open access

Takuma Hara, Hiroyoshi Akutsu, Tetsuya Yamamoto, Eiichi Ishikawa, Masahide Matsuda, and Akira Matsumura

Background Cushing's disease accounts for 4.7% of pituitary adenomas (1) , and typically patients show clinical symptoms of impaired glucose tolerance, hypertension, central obesity, moon face, osteoporosis, and psychosis (2) (3) . Gastric

Open access

Diana Catarino, Cristina Ribeiro, Leonor Gomes, and Isabel Paiva

pre-existing pituitary lesions (such as adenoma, Rathke’s cleft cyst, craniopharyngioma) ( 2 ) and can occur by either hematogenous spread or contiguous extension from adjacent anatomical sites (meninges, sphenoid sinus, cavernous sinus and skull

Open access

Guadalupe Vargas, Lourdes-Josefina Balcazar-Hernandez, Virgilio Melgar, Roser-Montserrat Magriña-Mercado, Baldomero Gonzalez, Javier Baquera, and Moisés Mercado

Background The vast majority of nonfunctioning pituitary adenomas (NFPAs) are either diagnosed incidentally on imaging studies performed for unrelated reasons or present with symptoms and signs of mass effect such as headache and visual field